NEW YORK, Nov 29 – DoubleTwist has licensed its annotated human genome database package to Merck, DoubleTwist announced Wednesday.
The two-year license agreement covers the database and software for visualizing and interpreting the gene information, which Merck and seven affiliated companies plan to use in drug discovery. Merck had previously used DoubleTwist’s bioinformatics software.
“We are pleased to expand our existing relationship with a leading pharmaceutical company such as Merck," DoubleTwist CEO John Couch said in a statement." Prophecy provides a secure way for Merck to rapidly access and integrate our regularly updated annotated data within its in-house software systems."
The parties did not disclose additional terms of the agreement.
DoubleTwist’s other pharmaceutical customers for its bioinformatics software have included Eli Lilly, Isis Pharmaceuticals, and Bristol Myers Squibb. But Merck is the first major pharmaceutical company to publicly sign on for DoubleTwist’s new database.